NASDAQ · Biotechnology

Incyte Corporation (INCY) Stock

$115.71 -1.04% NASDAQ: INCY Healthcare

Valuation

MetricValue
Price$115.71
Market Cap$23.45B
P/E Ratio15.15
P/B Ratio3.89
P/S Ratio4.29
EPS (TTM)$7.08
52-Week High$132.60
52-Week Low$82.82
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE29.70%
ROA20.48%
ROCE28.01%
Gross Margin52.77%
Operating Margin25.55%
Net Margin27.71%
Debt/Equity0.01
Current Ratio3.68

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0B$3.4B$3.7B$4.2B$5.1B
Operating Profit$586.0M$592.0M$655.0M$101.0M$1.3B
Net Profit$949.0M$341.0M$598.0M$33.0M$1.3B
EPS$4.27$1.52$2.65$0.15$6.41
Op Margin19.6%17.4%17.7%2.4%26.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$4.9B$5.8B$6.8B$5.4B$7.0B
Total Liabilities$1.2B$1.5B$1.6B$2.0B$1.8B
Cash$2.1B$3.0B$3.2B$1.7B$3.1B
Borrowings$45.0M$41.0M$38.0M$44.0M$69.0M

Latest News

2 Fast-Growing Pharmaceutical Stocks to Buy Now Motley Fool · Jul 9, 2026 Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside Trefis · Jul 8, 2026 Incyte to Report Second Quarter Financial Results Business Wire · Jul 8, 2026 RBC Capital Adjusts Incyte Price Target to $99 From $95, Maintains Sector Perform Rating MT Newswires · Jul 7, 2026 Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio Business Wire · Jul 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$749.0M$970.0M$496.0M$335.0M$1.4B
Investing Cash Flow$-389.0M$-156.0M$-255.0M$71.0M$-161.0M
Financing Cash Flow$-50.0M$-59.0M$-53.0M$-2.1B$-116.0M
Net Cash Flow$544.0M$894.0M$262.0M$-1.5B$1.4B
Free Cash Flow$568.0M$892.0M$449.0M$249.0M$1.4B

Valuation & Return Ratios

MetricValue
PEG Ratio0.19
EV / EBITDA10.30
FCF Yield7.69%
Quick Ratio4.58
Interest Coverage790.59
Return 1Y29.49%
Return 3Y110.46%
Return 5Y72.51%

Ownership

Insiders Held1.89%
Institutions Held106.59%
Institutions Float Held108.64%
Institutional HolderSharesReport Date
Baker Bros. Advisors, LP30,744,4122026-03-31
Blackrock Inc.18,978,1982026-03-31
Dodge & Cox Inc.12,252,3562026-03-31
Vanguard Capital Management LLC10,930,0662026-03-31
State Street Corporation9,641,3842026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AVBPArriVent BioPharma, Inc. $21.00 +9.38% -7.60 $1.04B 0.00%
CGEMCullinan Therapeutics, Inc. $14.37 -3.69% -4.60 $883.15M 0.00%
EXELExelixis, Inc. $64.53 -1.19% 17.78 $16.22B 0.00%
GMABGenmab A/S $29.00 -2.62% 21.45 $17.80B 0.00%
LEGNLegend Biotech Corporation $23.58 +0.17% -17.34 $4.36B 0.00%

About Incyte Corporation

Incyte Corporation is led by CEO William J. Meury, employs 2,844 people, headquartered in Wilmington, US, publicly traded since 1993.

Incyte Corporation (INCY) stock trades at $115.71 with a market capitalization of $23.45B. The stock is valued at a price-to-earnings (P/E) ratio of 15.15, price-to-book of 3.89, price-to-sales of 4.29. Over the past 52 weeks the stock has ranged between $82.82 and $132.60, and currently trades 12.7% below its 52-week high.

On profitability, Incyte Corporation generates a return on equity (ROE) of 29.70%, above the typical market range of roughly 12-15%, return on capital employed of 28.01%, an operating margin of 25.55%, a net profit margin of 27.71%.

In its most recent fiscal year, Incyte Corporation reported annual revenue of $5.1B, net profit of $1.3B. Revenue grew at an average annual rate of 14.0% over the last 5 fiscal years.

The balance sheet shows a debt-to-equity ratio of 0.01 (debt below half of shareholders' equity), a current ratio of 3.68, total assets of $7.0B, $3.1B in cash and equivalents.

INCY has an average daily trading volume of 1,715,363 shares, a beta of 0.77 (historically less volatile than the overall market).

Incyte Corporation by the numbers, 2016–2025

Between 2016 and 2025 Incyte Corporation reported revenue of $1.1B rising to $5.1B, a change of +364.8% across 10 years. Compounded, revenue has grown 14.0% a year over five years, 14.8% over three, 21.2% over the last twelve months. Net profit rose to $1.3B.

Operating margin went from 13.1% in 2016 to 26.1% in 2025, a gain of 13.0 percentage points. The most recent net margin is 27.71%. On a trailing twelve-month basis to Jun '26, revenue is $5.8B and net profit $1.6B.

Borrowings fell from $651.0M to $69.0M, cash from operations was $1.4B in the latest year, positive in 8 of the last 10.

Return on equity has averaged 14.1% over five years, and was 24.9% in the most recent year.

The share price itself has compounded at 3.6% a year over five years, 14.9% over three, 62.9% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Incyte Corporation (INCY) — frequently asked questions

What is Incyte Corporation (INCY) stock price today?

Incyte Corporation (INCY) is currently trading at $115.71, down 1.04% today.

What is INCY P/E ratio?

Incyte Corporation's P/E ratio is 15.15. This is between 15x and 30x, around the typical market average of roughly 18-22x.

What is INCY return on equity (ROE)?

Incyte Corporation's return on equity (ROE) is 29.70%. ROE measures net income relative to shareholders' equity. This is above the typical market range of roughly 12-15%.

What is Incyte Corporation's market cap?

Incyte Corporation has a market capitalization of $23.45B.

Does INCY pay a dividend?

Incyte Corporation is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does INCY carry?

Incyte Corporation has a debt-to-equity ratio of 0.01. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is INCY's profit margin?

Incyte Corporation reports a net profit margin of 27.71% — the share of revenue left after every cost, including tax and interest.

What sector is INCY in?

Incyte Corporation is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is INCY listed on?

Incyte Corporation trades on NASDAQ under the ticker INCY.

What is INCY's 52-week range?

Over the last year Incyte Corporation has traded between $82.82 and $132.60.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens INCY currently matches

On the figures above, Incyte Corporation passes the filters for 19 of our ready-made screens, among them High ROE Stocks, Quality Stocks, Low Debt Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

High ROE StocksQuality StocksLow Debt StocksHigh Profit Margin StocksHigh ROA StocksLow Debt High ROE StocksLarge Cap StocksHealthcare Stocks To BuyStock Screener StarterFree Stock Screener PicksStocks With PE Under 20High ROCE StocksDebt Free StocksHigh Gross Margin StocksStocks With PE Under 25Stocks With PE Under 30Debt to Equity Below 1 StocksHigh Current Ratio StocksLow Debt Large Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.